ATE547407T1 - Alkylthiopyrimidine als crth2-antagonisten - Google Patents
Alkylthiopyrimidine als crth2-antagonistenInfo
- Publication number
- ATE547407T1 ATE547407T1 AT08833849T AT08833849T ATE547407T1 AT E547407 T1 ATE547407 T1 AT E547407T1 AT 08833849 T AT08833849 T AT 08833849T AT 08833849 T AT08833849 T AT 08833849T AT E547407 T1 ATE547407 T1 AT E547407T1
- Authority
- AT
- Austria
- Prior art keywords
- alkylthiopyrimidines
- crth2 antagonists
- crth2
- antagonists
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/58—Two sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99538607P | 2007-09-25 | 2007-09-25 | |
| PCT/US2008/011053 WO2009042138A1 (en) | 2007-09-25 | 2008-09-24 | Alkylthio pyrimidines as crth2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE547407T1 true ATE547407T1 (de) | 2012-03-15 |
Family
ID=40039984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08833849T ATE547407T1 (de) | 2007-09-25 | 2008-09-24 | Alkylthiopyrimidine als crth2-antagonisten |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US8324229B2 (de) |
| EP (1) | EP2205569B1 (de) |
| JP (1) | JP5524847B2 (de) |
| KR (1) | KR20100061747A (de) |
| CN (1) | CN101874023A (de) |
| AR (1) | AR068632A1 (de) |
| AT (1) | ATE547407T1 (de) |
| AU (1) | AU2008305632B2 (de) |
| BR (1) | BRPI0817319A2 (de) |
| CA (1) | CA2700524C (de) |
| CL (1) | CL2008002826A1 (de) |
| CY (1) | CY1112720T1 (de) |
| DK (1) | DK2205569T3 (de) |
| ES (1) | ES2383249T3 (de) |
| HR (1) | HRP20120377T1 (de) |
| IL (1) | IL205647A0 (de) |
| MX (1) | MX2010003182A (de) |
| NZ (1) | NZ584352A (de) |
| PL (1) | PL2205569T3 (de) |
| PT (1) | PT2205569E (de) |
| RU (1) | RU2491280C2 (de) |
| SI (1) | SI2205569T1 (de) |
| TW (1) | TW200922587A (de) |
| WO (1) | WO2009042138A1 (de) |
| ZA (1) | ZA201002173B (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100061746A (ko) | 2007-09-25 | 2010-06-08 | 액티미스 파마수티컬스 인코포레이티드 | Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘 |
| KR20100095528A (ko) * | 2007-10-18 | 2010-08-31 | 베링거 인겔하임 인터내셔날 게엠베하 | 디하이드로티에노[3,2-ｄ]피리미딘의 제조방법 및 상기 제조방법에서 사용된 중간체 |
| EP2393492A1 (de) * | 2009-02-09 | 2011-12-14 | Boehringer Ingelheim International GmbH | Neue pharmazeutische zusammensetzungen zur behandlung von atemwegs- und gastrointestinalen erkrankungen |
| MY160036A (en) * | 2010-01-27 | 2017-02-15 | Boehringer Ingelheim Int | Pyrazole compounds as crth2 antagonists |
| EP2598145A1 (de) * | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmazeutische zusammensetzungen zur behandlung von atemwegs- und entzündungserkrankungen |
| EP2457900A1 (de) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten |
| TWI527809B (zh) | 2011-01-24 | 2016-04-01 | 百靈佳殷格翰國際股份有限公司 | 作為ｃｒｔｈ２拮抗劑之吡唑化合物 |
| US9206164B2 (en) | 2011-03-25 | 2015-12-08 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as CRTH2 antagonists |
| GB2494277A (en) | 2011-08-29 | 2013-03-06 | Univ Heriot Watt | Electro-spinning nanofibres onto a moving wire card |
| PL2781508T3 (pl) | 2011-11-17 | 2019-06-28 | Kbp Biosciences Co., Ltd. | Związki pierścieniowe o układzie skondensowanych pierścieni zawierające azot do zastosowania jako antagonisty CRTH2 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790679A (fr) | 1971-11-03 | 1973-04-27 | Ici Ltd | Derives de l'indole |
| GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
| WO1994008975A1 (fr) * | 1992-10-16 | 1994-04-28 | Nippon Soda Co., Ltd. | Derive de pyrimidine |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| JP2001302667A (ja) | 2000-04-28 | 2001-10-31 | Bayer Ag | イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体 |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| EP1413306A1 (de) | 2002-10-21 | 2004-04-28 | Warner-Lambert Company LLC | Tetrahydrochinolin-Derivate als CRTH2 Antagonisten |
| AU2003297398B2 (en) | 2002-12-20 | 2009-09-24 | Amgen Inc. | Asthma and allergic inflammation modulators |
| ATE316077T1 (de) * | 2003-04-25 | 2006-02-15 | Actimis Pharmaceuticals Inc | Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten |
| NZ548396A (en) | 2004-01-31 | 2010-06-25 | Actimis Pharmaceuticals Inc | Imidazo[1,2-C]pyrimidinylacetic acid derivatives |
| WO2007062677A1 (en) * | 2005-11-30 | 2007-06-07 | 7Tm Pharma A/S | Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands |
| KR20100061746A (ko) | 2007-09-25 | 2010-06-08 | 액티미스 파마수티컬스 인코포레이티드 | Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘 |
-
2008
- 2008-09-24 PT PT08833849T patent/PT2205569E/pt unknown
- 2008-09-24 AR ARP080104146A patent/AR068632A1/es not_active Application Discontinuation
- 2008-09-24 AT AT08833849T patent/ATE547407T1/de active
- 2008-09-24 DK DK08833849.6T patent/DK2205569T3/da active
- 2008-09-24 HR HRP20120377AT patent/HRP20120377T1/hr unknown
- 2008-09-24 WO PCT/US2008/011053 patent/WO2009042138A1/en not_active Ceased
- 2008-09-24 NZ NZ584352A patent/NZ584352A/en not_active IP Right Cessation
- 2008-09-24 MX MX2010003182A patent/MX2010003182A/es active IP Right Grant
- 2008-09-24 ES ES08833849T patent/ES2383249T3/es active Active
- 2008-09-24 BR BRPI0817319 patent/BRPI0817319A2/pt not_active IP Right Cessation
- 2008-09-24 JP JP2010526927A patent/JP5524847B2/ja active Active
- 2008-09-24 EP EP08833849A patent/EP2205569B1/de not_active Not-in-force
- 2008-09-24 AU AU2008305632A patent/AU2008305632B2/en not_active Expired - Fee Related
- 2008-09-24 CL CL2008002826A patent/CL2008002826A1/es unknown
- 2008-09-24 PL PL08833849T patent/PL2205569T3/pl unknown
- 2008-09-24 SI SI200830609T patent/SI2205569T1/sl unknown
- 2008-09-24 CA CA2700524A patent/CA2700524C/en not_active Expired - Fee Related
- 2008-09-24 CN CN200880117669A patent/CN101874023A/zh active Pending
- 2008-09-24 TW TW097136691A patent/TW200922587A/zh unknown
- 2008-09-24 US US12/679,895 patent/US8324229B2/en not_active Expired - Fee Related
- 2008-09-24 RU RU2010116293/04A patent/RU2491280C2/ru not_active IP Right Cessation
- 2008-09-24 KR KR1020107008867A patent/KR20100061747A/ko not_active Ceased
-
2010
- 2010-03-26 ZA ZA2010/02173A patent/ZA201002173B/en unknown
- 2010-05-09 IL IL205647A patent/IL205647A0/en unknown
-
2012
- 2012-05-07 CY CY20121100420T patent/CY1112720T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8324229B2 (en) | 2012-12-04 |
| US20100298361A1 (en) | 2010-11-25 |
| CA2700524C (en) | 2017-08-01 |
| AU2008305632A1 (en) | 2009-04-02 |
| AR068632A1 (es) | 2009-11-25 |
| SI2205569T1 (sl) | 2012-06-29 |
| KR20100061747A (ko) | 2010-06-08 |
| CY1112720T1 (el) | 2016-02-10 |
| ES2383249T3 (es) | 2012-06-19 |
| DK2205569T3 (da) | 2012-05-21 |
| JP5524847B2 (ja) | 2014-06-18 |
| HRP20120377T1 (hr) | 2012-05-31 |
| IL205647A0 (en) | 2011-07-31 |
| BRPI0817319A2 (pt) | 2015-03-17 |
| CL2008002826A1 (es) | 2009-08-07 |
| WO2009042138A9 (en) | 2009-10-15 |
| CN101874023A (zh) | 2010-10-27 |
| EP2205569A1 (de) | 2010-07-14 |
| MX2010003182A (es) | 2010-06-02 |
| CA2700524A1 (en) | 2009-04-02 |
| NZ584352A (en) | 2012-03-30 |
| WO2009042138A1 (en) | 2009-04-02 |
| ZA201002173B (en) | 2011-05-25 |
| JP2010540520A (ja) | 2010-12-24 |
| EP2205569B1 (de) | 2012-02-29 |
| AU2008305632B2 (en) | 2014-01-30 |
| PL2205569T3 (pl) | 2012-08-31 |
| RU2491280C2 (ru) | 2013-08-27 |
| PT2205569E (pt) | 2012-05-25 |
| RU2010116293A (ru) | 2011-11-10 |
| TW200922587A (en) | 2009-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151108T1 (xx) | Antagonisti nogo-receptora | |
| EP2170350A4 (de) | Substituierte imidazoheterocyclen | |
| ATE542825T1 (de) | Substituierte piperidino-dihydrothienopyrimidine | |
| DK2205737T3 (da) | Mikromirer | |
| DK2203462T4 (da) | Nukleosid-phosphoramidat-prodrugs | |
| DE602008006301D1 (de) | Koaxialnadelanordnung | |
| HRP20170963T1 (hr) | Modificirani saharidi | |
| DK2252395T3 (da) | Afsvovlingsmaterialer | |
| BRPI0807137A2 (pt) | Agentes antiparasitários | |
| ATE549340T1 (de) | Spiroindolinon-derivate als mdm2-p53 inhibitoren | |
| EP2128984A4 (de) | Gleichrichter | |
| DE602008002772D1 (de) | Polyvinylpyrrolidonpulverzusammensetzungen | |
| DK2132326T3 (da) | Fremgangsmåder | |
| BRPI0810926A2 (pt) | Antagonista de crig | |
| ATE547407T1 (de) | Alkylthiopyrimidine als crth2-antagonisten | |
| BRPI0814519A2 (pt) | Organopolissiloxano | |
| BR112012003701A2 (pt) | "novos antagonistas de quinolina-hepcidina" | |
| EP2211752A4 (de) | Biopulpa | |
| EP2149500A4 (de) | Elektronenstrahlensterilisator | |
| BRPI0817835A2 (pt) | Antagonistas cgrp | |
| ATE537149T1 (de) | Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten | |
| ATE533744T1 (de) | N-benzoypyrrolidin-3-ylamine als histamin-3 antagonisten | |
| DK2799428T3 (da) | Glucagon-antagonister | |
| EP2208322A4 (de) | Grid-router | |
| ATE512589T1 (de) | Dihydrochinolinone als ektoparasitizide |